Payne K A, Esmonde-White S
Caro Research, 620 Bord du Lac, Suite 305, Dorval, Quebec H9S 2B6, Canada.
Curr Hypertens Rep. 2000 Dec;2(6):515-24. doi: 10.1007/s11906-996-0035-6.
Real-world adherence to pharmacotherapy cannot be studied in the confines of the traditional clinical trial. Thus, to better understand adherence to antihypertensive medication in actual practice, a literature search was conducted to identify observational database studies of the use of antihypertensive medication. Ten studies were identified: half studied adherence patterns after initial prescriptions to patients with a new diagnosis of hypertension, and the others evaluated antihypertensive medication use in a mix of patients with newly diagnosed or chronic hypertension. Overall, results demonstrated that adherence to treatment for hypertension in the first year is very poor. In addition, it appears that initial treatment with newer classes of drugs, such as angiotensin II antagonists, angiotensin converting enzyme inhibitors, and calcium channel blockers favors treatment adherence. This review also highlights and discusses possible under-lying factors contributing to these results and implications for physicians.
在传统临床试验的范围内无法研究药物治疗在现实世界中的依从性。因此,为了更好地了解实际临床中抗高血压药物的依从性,我们进行了文献检索,以确定有关抗高血压药物使用的观察性数据库研究。共识别出10项研究:其中一半研究了初诊高血压患者首次处方后的依从模式,另一半评估了新诊断或慢性高血压患者混合群体中抗高血压药物的使用情况。总体而言,结果表明高血压患者第一年的治疗依从性非常差。此外,似乎使用新型药物(如血管紧张素II拮抗剂、血管紧张素转换酶抑制剂和钙通道阻滞剂)进行初始治疗有助于提高治疗依从性。本综述还强调并讨论了导致这些结果的潜在因素以及对医生的启示。